BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shwe TH, Pothacharoen P, Phitak T, Wudtiwai B, Kongtawelert P. Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells. Int J Mol Sci 2021;22:8755. [PMID: 34445462 DOI: 10.3390/ijms22168755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Choi B, Choi H, Kim H, Choi A, Kwon S, Mouli SK, Lewandowski RJ, Kim D. Z-domain protein nano-bio interfaced MRI visible anti-program death ligand-1 nanoconjugates for enhanced local immune checkpoint inhibitor immunotherapy. Nano Today 2022;45:101552. [DOI: 10.1016/j.nantod.2022.101552] [Reference Citation Analysis]
2 Escobedo-calvario A, Chávez-rodríguez L, Simoni-nieves A, Souza-arroyo V, Miranda-labra RU, Gomez-quiroz LE, Gutiérrez-ruíz MC. Tumor immune microenvironment modulation by cholesterol in hepatocellular carcinoma. Explor Dig Dis 2022. [DOI: 10.37349/edd.2022.00003] [Reference Citation Analysis]
3 Zhang L, Wang H, Tian J, Sui L, Chen X, Niu B. Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis. International Journal of Clinical Practice 2022;2022:1-10. [DOI: 10.1155/2022/3429462] [Reference Citation Analysis]